These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27846336)

  • 1. An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Role of Insulin Therapy In Diabetes.
    Rodbard HW
    J Fam Pract; 2016 Oct; 65(10 Suppl):S3-S7. PubMed ID: 27846336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intensified therapy with insulin analogs in type 2 diabetes: normalizing metabolism and maintaining body weight?].
    Jungmann E; Helling T; Jungmann G; Mertens C; Snelting U
    MMW Fortschr Med; 2000 Oct; 142(43):48. PubMed ID: 11098614
    [No Abstract]   [Full Text] [Related]  

  • 4. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
    [No Abstract]   [Full Text] [Related]  

  • 5. ["Living better--thanks to insulin"].
    Krankenpfl J; 2004; 42(5-6):167. PubMed ID: 15527229
    [No Abstract]   [Full Text] [Related]  

  • 6. [National practice guideline for diabetes. Managing your diabetic patient properly].
    Stiefelhagen P
    MMW Fortschr Med; 2002 Jul; 144(27-28):4-8, 10. PubMed ID: 12198877
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.
    Shanik MH
    Diabetes Technol Ther; 2012 Jun; 14(6):533-9. PubMed ID: 22364142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should the target A1C level be less than 7 percent? Yes: This should be the target for most patients.
    Peterson K
    Am Fam Physician; 2012 Dec; 86(12):1-2. PubMed ID: 23316992
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
    Riddle MC; Rosenstock J; Vlajnic A; Gao L
    Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insulin therapy in patients with type 2 diabetes].
    Siegmund T; Schumm-Draeger PM
    MMW Fortschr Med; 2008 May; 150(18):32-5; quiz 36. PubMed ID: 18533606
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.
    Feinglos MN; Bethel MA
    Cleve Clin J Med; 2005 Sep; 72(9):791-9. PubMed ID: 16193826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
    Lankisch MR; Del Prato S; Dain MP; Mullins P; Owens DR
    Prim Care Diabetes; 2016 Feb; 10(1):51-9. PubMed ID: 26150328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.
    Lin SD; Tsai ST; Tu ST; Su CC; Chen JF; Lu CH; Wang CH; Yu NC; Hsu SR; Hsieh MC
    Prim Care Diabetes; 2015 Apr; 9(2):135-41. PubMed ID: 25266893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical aspects of Insulin Lispro (LY275585)].
    Kuzuya T
    Nihon Rinsho; 1997 Nov; 55 Suppl():298-305. PubMed ID: 9434484
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review.
    Polinski JM; Connolly JG; Curtis BH; Seeger JD; Gaskins K; Perez M; Smith BF; Shrank WH
    Prim Care Diabetes; 2014 Jul; 8(2):101-9. PubMed ID: 24275103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin therapy in type 2 diabetes].
    Hummel M
    MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
    [No Abstract]   [Full Text] [Related]  

  • 18. Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study.
    Greven WL; Beulens JW; Biesma DH; Faiz S; de Valk HW
    Diabetes Technol Ther; 2010 Sep; 12(9):695-9. PubMed ID: 20687867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.
    Raccah D
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():76-82. PubMed ID: 18577159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.